Keep an eye on this one -- we like it long right here. Multi-year breakout above $40 last month now holding as support. Deep pullback to the 50dma with a large open interest put level at the 43-strike to act as support as well. Shorts are in covering mode down over -18.03% over the past 2-weeks. Options are moderately priced in the 19th percentile as well.
Identical setup to my Aug 6th call that resulted in 70% profit. Strong support at EMA 50 and oversold on the Hourly. Possibility of news tomorrow or Friday. Stop loss under today’s low.
The most attractive part of WAVE.V is share structure: 54M total float with 41M shares held by insiders / escrowed, leaving about 13M shares free trading. The company owns a portfolio of generic oncology drugs from which it generates over $300K of quarterly revenue. $1M in cash on hand. Based on last financials, they are $83K away from generating positive cash...
SONA shaved off close to 60% off its recent highs after news of 2 week delay for FDA approval of their COVID-19 test kits. Nothing has changed fundamentally and, if you read the NR carefully, they are lining up more customers and shipping kit prototypes under research license. NASDAQ uplisting is pending as well. The stock has landed in the historical support...
Q2 presentation scheduled for august 19th
Other Covid players are occupying the spotlight... However, INO chart analysis looks promising! Including: 1) Double bottom has occurred, as indicated by the bubbles 2) Stock price did not give up 23June2020 gains 3) Stochastic indicator shows an uptrend 4) Consolidation volume in play; pay-tience pays here 5) Nice wedge formation, looking for possible...
Took an entry here on swing trade on APT. Entry between $20.00 - $20.50. Stop Loss at: $19.40 (around 4%) -- You can even go tighter on this one if you'd like Profits: $24.00 (around 19% profit) Give us a follow and shoot us a Like for more analysis updates. Cheers! Disclaimer: I do not provide personal investment advice and I am not a qualified licensed...
Alpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment...
Relief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary...
Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020. If data are positive, regulatory approval could be achieved by the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to...
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI);...
DM.V is in breakout mode and could see serious appreciation from current levels. Steady orders of COVID-19 test kits are coming in, main AI business doing well, "sophisticated" investor taking big position last week to clear remaining warrants. Keep an eye on this one!
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque...
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency...
Alpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment...
Technical introduction I don't know who is going to read this so I am going to be a bit more detailed than normal to explain some of this indicators. The moving average convergence/divergence indicator, also known as the 'Mac D" defaul calculations is to that the differnce between the 12 period Exponential Moving Average (EMA) and subtract the 26 period EMA. ...
Hi all, Today I have come to publish this post as some inner voice forced me to do this. We reached all time high with respect to covid cases. We know covid shook the nations and disturbed our daily lives. Some of us forced into medieval ages through lock downs. Agony and Suffering are most sad things that humans can't escape but through God we can overcome them....
Lots of support arount $6. Waiting for FDA approval for its anti-viral fabric treatment. Recently signed multi-year deal in South Korea. Hot sector.